Tier 1 — highest

Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial

Guosong Liu, Jason G Weinger, Zhong-Lin Lu, Feng Xue, Safa Sadeghpour
Journal of Alzheimer's disease : JAD 2016 49(4):971-90

Bibliography

PubMed
PMID 26519439
PubMed Central
PMC4927823
DOI
10.3233/JAD-150538
Funding
See the original publication for study funding and the financial relationships associated with the proprietary MMFS-01 formulation.
Competing interests
A competing-interest declaration is not available in the indexed abstract or accessible disclosure metadata.

Study snapshot

DesignRandomized controlled clinical trial
ModelHuman participants
Sample44 adults aged 50–70 with cognitive complaints
InterventionMMFS-01 magnesium L-threonate formulation, 1.5–2 g/day according to body weight, or placebo
Duration12 weeks
EndpointsComposite cognitive performance; Executive function; Sleep and anxiety

What the study showed, in plain terms

This publication examines composite cognitive performance, executive function, sleep and anxiety. Study population or evidence base: 44 adults aged 50–70 with cognitive complaints. Intervention or exposure: MMFS-01 magnesium L-threonate formulation, 1.5–2 g/day according to body weight, or placebo.

Key findings

The active group improved on the composite cognitive score relative to placebo. Sleep and anxiety effects could not be separated clearly from placebo responses.

What this study can and cannot tell us

Small, short, formulation-specific study. It does not establish dementia prevention, and the studied amount of magnesium L-threonate was substantially above 250 mg/day.

Related papers in the corpus

Tier 1
A Magtein®, Magnesium L-Threonate, -Based Formula Improves Brain Cognitive Functions in Healthy Chinese Adults
Chengxiang Zhang et al. · Nutrients · 2022
Tier 1
Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial
Heather A Hausenblas et al. · Sleep medicine: X · 2024
Tier 1
The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial
Adrian L Lopresti et al. · Frontiers in nutrition · 2026
Tier 1
Oral application of magnesium-L-threonate enhances analgesia and reduces the dosage of opioids needed in advanced cancer patients-A randomized, double-blind, placebo-controlled trial
Siyin Wu et al. · Cancer medicine · 2023
Tier 1
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Therapeutic Effect of Magnesium-L-Threonate Supplementation for Persistent Pain After Breast Cancer Surgery
Yuncheng Ni et al. · Breast cancer (Dove Medical Press) · 2023
Tier 3
Enhancement of learning and memory by elevating brain magnesium
Inna Slutsky et al. · Neuron · 2010

Citation network

Articles citing this research paper

5 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Biohack Blueprint Research